Imran Ali is the Senior Manager of the pan-Canadian Pharmaceutical Alliance Office and has been in the role since September 2015. From 2012 to 2015, Imran held the position of Senior Manager with the Agreements & Negotiations Unit in the Ontario Ministry of Health and Long-Term Care’s Negotiations Branch. In this role, Imran provided leadership and direction for planning, priority setting and negotiation of accountability agreements with individual providers and health care organizations to optimize the Ministry’s investment in the health care system valued at over $11 billion annually. Imran provided support for the negotiations process with the Ontario Medical Association (OMA). Prior to this, Imran supported the negotiations of the 2012 Physician Services Agreement with the OMA and lead the coordination of subsequent implementation activities related to the agreement. He also served as the Ministry Co-Chair for the Systems Management Committee, which is responsible for bilateral monitoring and analysis of physician services in Ontario with the OMA. Imran began his career with the Ministry in 2006 with the Primary Health Care Branch where he managed physician services contracts valued in excess of $50 million annually in the Specialized Models Unit. Imran graduated with a Masters in Public Health specializing in Health Policy and Management from the University of Alberta's School of Public Health in 2005.
Mitch assumed the role of Assistant Deputy Minister, Pharmaceutical Services Division on August 11, 2017.
Prior to his current assignment as Assistant Deputy Minister, Mitch was the Executive Director of the Division's PharmaCare Information, Policy and Evaluation Branch where he was responsible for guiding the development, evaluation and research of pharmaceutical policies that support equitable and sustainable patient access to effective drug therapy. A key accomplishment was the drafting of BC’s Pharmaceutical Services Act, a comprehensive legislative framework for the one-billion dollar BC PharmaCare program.
Mitch joined the Public Service in 2001 as a Ministry of Health Communications Officer and has been with the Pharmaceutical Services Division since 2004, progressively taking on increasing responsibilities.
Mitch obtained a Bachelor's degree in Journalism and Communication at the University of Regina, which at the time was the only journalism program in Western Canada. He worked as a print journalist and editor at during a 14-year career in that field. He obtained a Graduate Certificate in
Health Systems Leadership in 2008.
Deborah Maskens, is a kidney cancer patient and patient advocate. Her current roles include Vice-Chair of the International Kidney Cancer Coalition (IKCC). Along with another patient, she Co-Founded Kidney Cancer Canada and played an active role for 10 years. During this time she focused on advocacy, health technology assessment, and patient navigation.
Deb is currently a Patient Advocate on the NCI Renal Task Force. She is a also a Patient Panel member of the HTAi Patient and Citizen Involvement group (HTAi.org) and Co-Lead of the CanCertainty Coalition campaign of 35 cancer organizations advocating for health policy change across Canada (CanCertainty.ca).
In 2016, Deb was awarded the Canadian Governor General’s Meritorious Service Medal, Canada’s highest award for her dedication and professionalism in patient advocacy and volunteer service.
Deb is a frequent speaker at national and international cancer meetings where she provides the patient voice perspective, along with sound advocacy knowledge and experience.
Karen Voin is Vice President, Group Benefits and Anti- Fraud at the Canadian Life and Health Insurance Association (CLHIA). Karen is responsible for overseeing and advocating for the industry's extensive interests related to health and disability insurance, and the industry’s anti-fraud strategy.
Karen joined CLHIA in 2011. Prior to joining CLHIA, Karen worked in various life and health insurance organizations in a leadership capacity.
Eric Tse is the General Manager for Shire in Canada. As the head of one of the fastest growing biotechnology companies in the country, he is responsible for pursuing and accelerating the Canadian expansion of Shire with a special focus on the areas of rare diseases and other high-need conditions.
Since joining Shire in October 2013, Eric has led the Canadian team through a series of successful transformations, including two integrations and the consolidation the company’s commercial operations under a single corporate entity, both strengthening and expanding the Shire footprint in Canada.
Under his leadership, Shire also implemented a comprehensive, best-in-class patient assistance program for Canadians living with rare diseases, in addition to achieving leadership positions in the areas of ADHD and ulcerative colitis in Canada.
Today, following the recent combination with Baxalta, Eric is at the helm of an expanded, Shire team, with increase capabilities and a renewed focus to enable people with rare diseases and other highly specialized conditions to lead better lives.
Eric is a Board Member of BIOTECanada. He holds an MBA from the University of Toronto’s Rotman School of Business and a BA from Queen’s University, Kingston, Ontario.
As a doctor trained at the Université de Sherbrooke and a specialist in public health, he holds a master’s in health administration from the Université de Montréal and a fellowship from the Canadian Health Services Research Foundation. In addition to his clinical experience—particularly in emergency medicine—over the last 25 years, he has acquired solid experience in the management of health institutions and public health organizations, as well as the regional and national governance of health systems, while participating in and managing several projects. At the international level, he has also implemented and directed many study projects and missions, particularly in Africa. Between 1993 and 2001, Dr. Boileau assumed the ministerial mandate of Director of Public Health, and between 2001 and 2008, the role of President and Director General of the Agence de la santé et des services sociaux de la Montérégie, a region of 1.5 million people located southwest of Montréal. In October 2008, the Government of Quebec appointed him as President and Director General of the Institut national de santé publique du Québec, a central organisation gathering the public health expertise required by the health and social services network in the province. Ambassador of the Université de Sherbrooke for which he acts as an associate professor, as well as the Université de Montréal, he is an active member on board of directors of prestigious organizations such as the Canadian Institute for Health Information, the Canadian Foundation for Healthcare Improvement, the Quebec Network for Personalized Health Care and the Institut de Recherches Cliniques de Montréal.
John Anacleto is the Director of Payer Relations with McKesson Canada and is responsible for various private and public payer engagements. He has over eleven years of experience working in the pharmaceutical industry serving multiple pharmaceutical manufacturers and government institutions.
Prior to his current role, John was with TELUS Health Analytics, managing a team that provided consultation on the Canadian reimbursement landscape and insurance market trends. Client engagements included providing strategic input on how to engage the private and public insurance industries in Canada and data to support market access strategies. His knowledge on the Canadian reimbursement landscape spanned various therapeutic areas, including but not limited to: oncology, arthritis, diabetes, pain and vaccines.
As a consultant, John’s economics background was invaluable in constructing Budget Impact Assessment models, patient assistance financial models, analyzing patient access for private and public insurance, analyzing claims data to determine drug and patient costs, and calculating patient’s ability-to-pay for medication.
He has also written several articles on access to insurance coverage in Canada, plan design and longitudinal trends in private plans, and plan sponsor health benefit trends.
Nadia Turchetta is the Executive Director of Biosimilars at Sandoz Canada. Nadia joined Sandoz in January 2016 after spending almost 13 years at Novartis, where she worked in different roles including sales, market research, marketing and sales management.
Nadia’s academic background includes an Honors Bachelor of Business Administration at the Richard Ivey School of Business, University of Western Ontario.
Nadia is also an active member of Biosimilars Canada and a co-chair of the Canadian Biosimilars Forum.
For over a decade Sandoz, a Novartis division, has been the pioneer and global leader in biosimilars. This year marks ten years since Sandoz launched the world’s first biosimilar, Omnitrope®, in the EU, giving rise to the era of affordable biologics that have helped to treat millions of patients and liberate billions of dollars in healthcare costs. Sandoz continues to invest in research and development into these life changing medicines.
ohn-Paul is Director, Reimbursement Strategy at PDCI. He brings more than 20 years of experience working in the health and pharmaceutical sectors. Prior to joining PDCI, John-Paul was Founder and Managing Director of Roubaix Strategies Inc.(RSI), and previously spent the better part of a decade in market access leadership roles, negotiating drug listing agreements for the reimbursement of innovative pharmaceuticals in Canada. His experience and knowledge in market access and negotiation strategy covers an extensive scope therapeutic and business areas, including strategic insights on how to obtain and maintain product reimbursement in both private and public drug plans.
John-Paul has led successful reimbursement strategies and negotiated funding agreements for conventional and specialty care products across Canada. He has worked with companies on successful strategies for the reimbursement of Drugs for Rare Diseases, Oncology and Biomarker Testing, Cardiovascular and Diabetes, Neuroscience, and Consumer Healthcare.
At PDCI, John-Paul leads the Reimbursement Strategy Team and focuses on the development and implementation of strategic public and private reimbursement strategies, market access assessments and new policy impact analyses and assessments.
John-Paul also brings with him the RSI Negotiations Strategy Training Programme. Combining many years of experience, the Programme delivers a tailored negotiation approach aimed at addressing the unique needs of our clients and preparing them for pCPA and other pricing and market access negotiations.
A sought-after speaker, strategist, and thought leader, John-Paul brings a keen understanding of the inter-relationships between public and private drug markets in Canada, having engaged extensively across both systems.
Prior to his career in the pharmaceutical industry, John-Paul worked work for several years with two major health professional associations in Ontario. This work included the successful negotiation of the first-ever agreement with the Ontario Government for compensation of pharmacies delivering influenza immunization clinics. He also spent several years working as an advisor in Federal and Ontario governments.
John-Paul holds a BA in Political Science from St. Jerome’s University (at Waterloo), and an Executive Certificate in Marketing Management from the Schulich School of Business. He is an active member of the Canadian Association for Healthcare Reimbursement, and BioteCanada (BTC), serving on BTC’s Health Advisory Board and Orphan Drug Working Group.
An avid cyclist and drummer, you may also be lucky enough to see John-Paul cycling to band rehearsal.
Originally from Vancouver, Alan Birch currently resides in Toronto. He is an administrator at the Oncology Drug Access Navigators of Ontario (ODANO). Within ODANO, Alan facilitates education for fellow members, does advocacy for patients as well as maintaining the ODANO website at www.odano.ca. In addition to ODANO duties, Alan is a drug access navigator at North York General Hospital.
Alan is a Pharmacy Technician by background and has been working in oncology for the past 5 years. He is a member of the Ontario College of Pharmacists and the Ontario Pharmacists Association.
Kaitlyn Proulx is PDCI Market Access’ Managing Director and is responsible for managing the firm and leading the staff of twenty senior consultants and supporting staff. By offering full-service strategic pricing and market access consulting services, Kaitlyn and her team assist clients across all stages of pricing and reimbursement activities.
Kaitlyn provides ongoing advice with respect to pricing and reimbursement strategy to help ensure timely listing on drug plan formularies. She maintains a strong working relationship with drug plan managers across Canada facilitating access to payers, decision makers and the latest information on drug plan policies and regulations.
As the National Practice Leader, Drug Benefits Solutions in Great-West Life’s Toronto Group Sales Office, Barbara A. Martinez supports sales offices across Canada on prescription drug management initiatives. She plays a key role in supporting advisors and their clients, including designing and managing drug benefit plans with Great-West Life Drug Solutions programs.
Barbara joined Great-West Life in 2012 after 10 years at Mercer, where she led the Canadian drug benefits consulting team. She’s a regular speaker at industry forums and a frequent commentator on employer drug programs. Her past experience also includes 13 years in the pharmaceutical industry, where she worked in sales and marketing as well as government and professional affairs.
Michèle Chadwick is the lead on the Regulatory Review of Drugs and Devices Team within the Health Products and Food Branch.
Michèle has worked within the Federal Health Portfolio for 18 years both Health Canada and Public Health Agency and Health Canada in various policy and regulatory capacities, predominantly in the realm of therapeutic products.
Prior to coming to the federal government she worked in the pharmaceutical Industry for 10 years.
Fun fact: Up until recently Michèle was an avid runner. She qualified for and ran the Boston Marathon, completed 8 marathons, 15 half marathons. Due to injury she has moved on from running to rowing.
Chris Goguen is the Strategic Pharmaceutical Partnerships Lead within the Drug Management Solutions team at Medavie Blue Cross. The focus of his role is strengthening Medavie’s business relationships with the pharmaceutical industry, to design services and agreements that result in savings for plan sponsors, and to mobilize innovative partnerships that advance improved health outcomes.
Chris joined Medavie Blue Cross in 2015, with 25 years of experience as a senior leader within the research-based pharmaceutical industry in Canada. With the majority of his career focussed on External Affairs, including strategy and relationship development with governments, private payers & other health stakeholders across Canada, Chris has developed expertise in drug pricing, access, negotiation and patient health management strategies. He has played a lead role in development and implementation of numerous disease [drug] management partnership programs, impacting both public and private health system outcomes.
Laurene (Redding) holds a Bachelors of Science in both Biology and Pharmacology as well as a Masters of Business Administration in Health Services Management, both from McMaster University, in Hamilton, Ontario. Laurene has spent well over 20 years working in the Canadian pharmaceutical industry in both market access and commercial positions of increasing levels of responsibility at Sanofi, Roche, Novo Nordisk and most recently Takeda. In addition to working within the pharmaceutical industry, Laurene has experience working for the Ministry of Health (Ontario) and in hospital health services in Canada. In her eight years tenure at Takeda, Laurene held an executive leadership position growing Takeda from a start-up to a mid-sized pharmaceutical company in the top 20 and top 5 for growth, in Canada. Her areas of responsibility included overseeing commercial and access strategy, contributing to corporate planning, organizational design, cross-functional brand planning and launch readiness in addition to direct responsibility for leading the patient support programs, pricing, corporate communications, government relations, contracting, tendering, health economics and health policy work for the Canadian affiliate. Laurene has experience working in both primary care and specialty medicines, in a number of therapeutic areas, specifically in rheumatology, oncology/ oncology supportive care, gastroenterology, respiratory, hematology, endocrinology and cardiometabolic disorders, CNS/ mental health, genito-urinary, renal and internal medicine.
As a former senior staff member and negotiator for CMA’s- Manitoba Division, Executive Director for Manitoba Pharmacists, and with over 16 years’ experience in market access & government affairs with GlaxoSmithKline, UCB and now Valeant Canada, Doug brings a wide range of related experiences to the Market Access Summit.
Lorna has successfully held senior leadership roles in a number of national charities over the past twenty years, and has a diverse background in fundraising, communications, strategic planning and mission development. Lorna spent the past eleven years working with The Leukemia & Lymphoma Society of Canada, most recently as Senior National Director, Mission Programs & Corporate Communications. She has a stellar reputation and is frequently asked to present on the emerging trends and critical issues in the Canadian lymphoma landscape.
Ms. Childerhose’s career is focused on optimizing patient outcomes through forming meaningful relationships in the Canadian health care system.
Her career path took her to government early on where she embraced challenges in public relations to improve communications about issues impacting the public in various portfolios, including the Senior’s and Women’s Secretariats, Transportation, Tourism, and Health Care. She was the Communications Lead for the Ministry of Health’s Change Management initiative to change the business model of siloed departments to cross-functional teams, improving communications, optimizing ministry outcomes, and strengthening program accountability.
As the Director for Rx&D (now IMC) in Ontario, Ms. Childerhose led industry initiatives during an especially active time with the goal of advancing industry’s patient-focused value proposition, and economic benefit spin-offs.
Joining Valeant Canada and Bausch + Lomb provided Ms. Childerhose with the opportunity to collaborate directly with the leading Canadian innovative pharmaceutical and medical device organization where she develops and implements strategies to increase the number of innovative products available to Canadians, ensuring business growth and the related health and social benefits for Canadians.
Ms. Childerhose lives in Mississauga with her husband and two daughters.
With over 25 years of experience in public affairs, lobbying, and management under his belt, Alain isn’t just an expert—he’s a pillar of the communications and public relations industry in Quebec. He maintains close relationships with his clients as a Quebec government relations specialist, earning recognition and appreciation for his work as a consultant. Alain has an excellent grasp of the national and provincial political issues influencing such sectors as health, natural resources, the environment, finance, and the pharmaceutical industry.
Before joining Citizen Relations, Alain was vice president, government affairs at McKesson Canada. This acknowledged bio-pharmaceutical industry expert cut began his expertise at Smithkline Beecham Pharma as director of health policy and strategic relations, at Solvay Pharma as government relations manager, and finally at AstraZeneca Canada as regional manager of government relations. He also operated as a professional in this sector as a strategic consultant for many years.
As a public relations professional, Alain began his fructuous career at Orkestra, Affaires Publiques before moving to NATIONAL Public Relations as a senior consultant, then as a vice president.
Alain also had the pleasure of working with the Quebec Brewers Association, serving as president for almost three years, allowing him to gain significant insight in interprovincial, environmental and industrial trading.
Mrs. Karine Alloul currently holds the position of Senior Manager, Health Economics and Health Outcomes at Sanofi. Over the past decade, she has covered a variety of therapeutic areas including cardiovascular disease, central nervous system diseases and more predominantly oncology. Karine holds a Bachelor in Pharmacy and a Master’s degree in Pharmaceutical Sciences focusing on drug development from the University of Montreal. Karine has over 20 years' experience working in the pharmaceutical industry, where she held various positions in clinical research, market research, sales training and market access. She has led innovative outcomes research projects measuring the impact of health management interventions conducted in collaboration with private payers and employers. Her other fields of expertise include assessing quality of life in cancer patients, assessment of treatment patterns, and validation of outcomes in real world settings in partnership with payers.
Neil Corner leads the Health Access and Outcomes division for the Canada business unit of QuintilesIMS . In this role he is focused on supporting federal and provincial government, academics and the pharmaceutical industry in understanding and delivering health outcomes data, economic modelling, payer research and access strategies.
Neil’s team utilizes data from Electronic Medical Records, prescription data, claims data, patient reported outcomes and administrative data sources to support the appropriate evidence creation for a pharmaceutical or medical device intervention. He has lead the development of strategic partnerships, with groups such as the Hub Research Centre at St Michael’s hospital to bring together cutting edge methodologies and the most robust EMR data available for research.
Neil has more than 25 years of pharmaceutical industry experience in the UK, US, EMEA and Canada.
Jeremy Slobodan is the Director, Drug Utilization, Information & Stewardship for Alberta Health Services and is based out of Red Deer. His position oversees the AHS drug formulary, drug information and antimicrobial stewardship for Pharmacy Services.
In part, his role includes improving patient care through optimized drug use and working with practitioners to ensure new drugs introduced onto the AHS formulary provide improvements to the health care system.
Jeremy is the Chair of the National Hospital Formulary Collaborative, a member of the Alberta Health Expert Committee on Drug Evaluation & Therapeutics and a past president of the Alberta Pharmacists Association."
Christopher Trevors, MS, CGC graduated with a B.Sc. (Honours) in Biology from Queen’s University and a master’s degree in Human Genetics (Genetic Counseling) from Sarah Lawrence College in Bronxville, New York. He worked at the Westchester Medical Center in Hawthorne, New York before starting at The Hospital for Sick Children (SickKids) in Toronto as a genetic counsellor. During his nine years at SickKids he was involved in clinical care before taking on a role as a clinical educator and evaluator in the areas of genetics, ethics and molecular/genomic technologies. Christopher worked as Canadian General Manager of Centogene AG, a German molecular diagnostics company for 3 years before transitioning to help build a genetic diagnostics division at LifeLabs in Toronto as Director of Genetics and Genomics. Christopher is currently the National Director of Genetic Health Solutions at Dynacare and continues to lecture in the University of Toronto Genetic Counselling MSc program, the Medical Laboratory Technology Program at The Michener Institute and the George Brown Nursing Program.
A career public servant, Doug has a background in international trade law, intellectual property policy, pharmaceutical industry issues and competition law enforcement.
Doug attended McGill University, the University of New Brunswick and l'Université de Moncton. He graduated law school in 1997 and was called to the Ontario Bar in 1999 after a clerkship with the Honourable Marc Noël of the Federal Court of Appeal.
In 2000, Doug was hired by Industry Canada to assist in the case management of two WTO-based legal challenges to Canada’s pharmaceutical patent regime brought by the US and EU. In 2006, Doug became the Director of the Patent and Trademark Policy Directorate at Industry Canada, where he led a number of legislative and regulatory initiatives under the Patent Act and Trademarks Act, including the development of Canada’s Access to Medicines Regime (CAMR) and pharmaceutical patent litigation reform. In 2009, Doug joined the Competition Bureau as Assistant Deputy Commissioner, Civil Matters Branch, where he was responsible for a number of high profile prosecutions under the Competition Act.
Doug became Executive Director of the PMPRB on October 28, 2013.
Heather is currently the Director of Healthcare and Innovation at Roche Canada, responsible for Personalized Healthcare, Foundation Medicine, Biologic Strategy and Strategic Account Management. She currently sits as the Chair of the Operating Committee for the Canadian Pharmaceutical Distribution Network (CPDN) and has worked on various other industry association committees. Heather has over a decade of experience working in the Pharmaceutical industry, with a strong focus in oncology. She has worked on both the clinical development side and on the commercial side in various roles such as Global Project Management, Account Management, Corporate Development, Operations Management and Biologic Strategy. The cross-functional nature of her roles has provided her with knowledge in strategic corporate ventures, laboratory diagnostics, patient programs, biosimilars, medical affairs, market access and government relations. Heather holds an HBSc. in Biology from the University of Western Ontario and a Project Management Professional (P.M.P.) designation.
As Director, Strategic Partnerships at the Institute for Clinical Evaluative Sciences (ICES), Alison Paparica leads work to explore and evaluate new initiatives that have the potential to become ICES core business. This includes ICES work with the private sector, which began as a pilot in 2015 and is now a regular service offering, and new initiatives such as the Pan-Canadian Real-world Health Data Network - PRHDN. In addition, she serves as the main coordinating point of contact with key ICES partners including Health Quality Ontario, Cancer Care Ontario and the Ontario SPOR SUPPORT Unit. Alison is also Assistant Professor (Status) at the Institute for Health Policy, Management and Evaluation at the University of Toronto.
Prior to joining ICES, Alison was the Director of the Planning, Research & Analysis Branch at the Ontario Ministry of Health & Long-Term Care, responsible for up to $60 million annual investment in health services and population health research, and extensive knowledge translation and exchange activities to ensure that research findings were understood and used in health system policy development and planning.
From 1994-2001, Alison worked in international pharmaceutical R&D at Eli Lilly, Astra Pharma, and Genpharm Inc. She has her PhD in organic chemistry from the University of Western Ontario, Project Management Professional (PMP) certification since 2001, and was a fellow in Canadian Foundation for Healthcare Improvement's EXTRA program.
Sarah Lyons is the Chief Operating Officer of Privacy Analytics, a Canadian QuintilesIMS company specializing in data de-identification enabling health analytics while protecting patient privacy.
Sarah has over 15 years of experience in professional services, software development and operations management. She has extensive experience leading large business transformations and advising clients across industries on enterprise risk management, privacy and governance.
Before joining Privacy Analytics, Sarah was a Partner and National Privacy Leader at MNP LLP. Sarah joined MNP through its merger with A Hundred Answers Inc., a professional services firm where she was COO and delivered advisory, digital and technology solutions and services. Sarah has led the development and implementation of innovative risk assessment methodologies for the federal government, large financial institutions, and Fortune 500 companies. She previously led the establishment of new consulting markets and methodologies for Ernst & Young’s growing Government and Public Sector practice, where she also managed large-scale projects with over 35 direct reports. She has provided privacy advisory services in Canada and globally across jurisdictions, including in the health sector and for privacy regulators.
Sarah has a Master of Applied Science in Electrical Engineering, holds professional certifications in audit, risk management and control and is a Privacy by Design Ambassador.
Brad Millson is a Principal within the Health Access and Outcomes consulting group at QuintilesIMS.
Brad leads projects to deliver market access strategy and real-world evidence-based solutions for the pharmaceutical industry and its stakeholders. He joined the company in 2013, bringing his global expertise in pharmaceutical brand management, strong medical science training and strategic problem solving to the team.
Brad has over 15 years of experience in the Life Sciences industry globally, across government and private sectors. In Canada, he is recognized for his expertise in health outcomes, market access and policy strategy.
Prior to joining QuintilesIMS (formerly IMS Brogan), he led the investment attraction function for Life Sciences at the Department of Foreign Affairs and International Trade, assisting global life science companies entering the Canadian market. Brad spent several years in the US at a leading biotech strategy consulting firm, developing solutions in new product launch, marketing, sales, and business development for the global headquarters of top pharmaceutical and biotech companies, spanning key therapeutic areas such as Oncology and Immunology
Brad is a Dean’s List graduate of the MBS program (integrated MSc Biotech + MBA ) at Keck Graduate Institute in Claremont, California, and holds a BSc in Physiology from McGill University. Brad speaks English and French, and is conversational in Mandarin Chinese.
Neil Palmer is Founder & Principal Consultant of PDCI Market Access Inc (PDCI) a leading pricing and reimbursement consultancy founded as Palmer D’Angelo Consulting Inc (PDCI) in 1996.
He leads a senior team of market access professionals with pricing & reimbursement engagements covering Canada, Europe, and the United States. In December 2006, PDCI became a subsidiary of RTI Health Solutions of RTP North Carolina where Neil served as global vice president before re-acquiring the company in 2009.
Prior to PDCI, Neil worked with the Canadian Patented Medicine Prices Review Board (PMPRB) where his responsibilities included policy development, overseeing the price review of patented medicines and conducting economic research. Prior to the PMPRB, he worked with the Health Division of Statistics Canada where he was responsible for economic and statistical analysis of health care costs and utilization.
After completing his studies at the University of Western Ontario, Neil began his career in Montreal with the research group of the Kellogg Centre for Advanced Studies in Primary Care.
He has written extensively on pharmaceutical pricing and reimbursement issues and is a frequent speaker at conferences in North America and Europe. Neil is also Adjunct Assistant Professor at the University of Southern California School of Pharmacy graduate program in Health Care Decision Analysis where he lectures on health technology assessment, pricing and market access from a global perspective.
Pamela Fralick is an experienced leader who has been fostering positive change in Canada’s health sector for decades. Throughout her career, Ms. Fralick has distinguished herself in a variety of senior roles. A convener and innovator, Ms. Fralick is one of Canada’s leading, compassionate voices in the health sector. As the President of Innovative Medicines Canada, Ms. Fralick leads the industry association for Canada’s innovative pharmaceutical companies, working with its members and communities to ensure Canadians have access to the medicines they need, when they need them. Prior to joining Innovative Medicines Canada, Ms. Fralick was President and CEO of the Canadian Cancer Society, Canada’s largest health charity, where she oversaw a three-year process of intense transformation, resulting in historic changes to the operational and governance structures of the organization. Ms. Fralick previously served as president and CEO of the Canadian Healthcare Association (CHA) and as CEO of the Canadian Physiotherapy Association. At both Associations, Ms. Fralick led organizational initiatives designed to enhance sustainability and improve outcomes for the associations, their members and stakeholders. Ms. Fralick has also held senior positions with the Canadian Centre on Substance Abuse and Health Canada’s Alcohol and Other Drugs Unit. True to her commitment to the health and well-being of Canadians, Ms. Fralick has served on numerous prestigious boards and collaboratives across Canada. She was Chair of the Health Action Lobby (HEAL) and Co-chair the Canadian Coalition for Public Health in the 21st Century (CCPH21). She has been active in many organizations as a senior volunteer, including the Centre for Addiction and Mental Health, the University of Ottawa Institute of Mental Health Research, Triathlon Canada and the International Triathlon Union. She is currently on the board of Outward Bound Canada (Chair) and the Canada Dance Festival (Past Chair). Ms. Fralick has a BA in French and psychology and an MA in developmental psychology from Carleton University, as well as a Master of Public Administration (MPA) from Queen’s University. She also holds an ICD.D designation. She is trilingual – in English, French and German – and is an accomplished artist and athlete.
Mark Lachovsky is the founder and President of Accel Pharma Inc., a private generic company based in Montreal. With over 30 years’ experience in the Canadian pharmaceutical market, Mark developed a business model with a unique angle in the generic market. By focusing on public and private payers as the customer, Accel Pharma has been able to secure exclusive listings while providing cost savings to the payers.
Mark has gained expertise in both the brand and generic market sectors over the years. Starting his career in Business Development, Mark moved through various segments of the industry with increasing responsibility including licensing, sales, customer service, product management and general management.
A key focus of his career has involved licensing from companies throughout the world. Mark is also involved in providing consulting services to companies on key strategic areas of their business.
On the personal front, Mark is an avid photographer focusing on capturing the essence of life. From the wilds of Africa to his backyard, Mark has captured unique images portraying nature and people. He has been published in various magazines.
Coming from the healthcare sector and with an international academic background in business administration, Sebastien is an innovative Public Affairs Executive with a multidisciplinary vision of the Healthcare industry. Over the past 18 years, Sebastien has developed a recognized expertise in the management of the pharmaceutical and Medical device industry, having had the opportunity to work in various functions, accumulating various notorious successes throughout his professional career. He currently leads the Government Relations and Market Access Team at Baxter Corporation.
In 2015, Sebastien had the honor to participate to the Governor General's Canadian Leadership Conference, serving as co-chair in the course of the program. He currently sits on the board of directors of the SEMAFO Foundation and is involved in various causes related to the field of healthcare and wellness.
Sebastien holds a B.Sc. from the Université du Québec à Montréal, an MBA from the University of Paris-Dauphine and is currently a candidate for a Graduate Diploma in International Relations from the London School of Economics and Politics.